How much weight can you lose on Foundayo?

Every approved GLP-1 drug so far has meant either a weekly injection or, for oral semaglutide (Rybelsus), a fasted morning pill with strict water limits. Foundayo, the brand name for orforglipron, changes both constraints at once: it is a once-daily tablet with no injection and no food or water timing rules. The FDA approved it on April 1, 2026, making it the first small-molecule, non-peptide GLP-1 receptor agonist cleared for chronic weight management.2

What makes Foundayo different from other GLP-1 drugs?

Semaglutide and tirzepatide are peptides - large molecules that must either be injected or, in Rybelsus's case, paired with an absorption enhancer and taken on an empty stomach with limited water. Orforglipron is a small molecule built from scratch to activate the same GLP-1 receptor without needing that peptide structure, which is why it can be manufactured more simply and taken without the fasting rules oral peptide drugs require.2 It was studied in a Phase 3 program called ATTAIN, with the pivotal trial in adults without diabetes registered as NCT05869903 and published in the New England Journal of Medicine in November 2025.1

How much weight did people lose in the trial?

The FDA label reports results from two trials at week 72. Trial 1 enrolled adults with obesity or overweight who did not have diabetes; Trial 2 enrolled adults with type 2 diabetes.3 Weight loss was dose-dependent and larger in the non-diabetes group, consistent with how other GLP-1 drugs perform across these two populations.

Source: FDA-approved prescribing information for Foundayo, mean percent body weight change from baseline at week 72.3 Figures are averages across all randomized participants regardless of completion; individual results vary.

How do you actually take it?

Dosing starts at 0.8 mg once daily, rising to 2.5 mg at week 4 and 5.5 mg at week 8.3 From week 12 onward, the dose can be increased further to 9 mg, 14.5 mg, or the maximum 17.2 mg, with each step held for at least 30 days before the next increase.3 Tablets are swallowed whole - the label specifically warns against breaking, crushing, or chewing them - and can be taken with or without food, at any time of day.3

"A pill with no injection and no fasting rule removes two of the biggest reasons people give up on GLP-1 treatment before it works."

Who is it approved for, and who should avoid it?

Foundayo is approved for adults with obesity (BMI 30 kg/m² or higher) or who are overweight (BMI 27 to under 30) with at least one weight-related condition, such as high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease.3 The pivotal trial excluded anyone with type 1 or type 2 diabetes, a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, or a recent weight change of more than 5 kg.1 Those exclusions mirror the standard precautions already in place for injectable GLP-1 drugs.

What side effects should you expect?

The most common adverse reactions, each occurring in 5% or more of patients, were gastrointestinal: nausea (26-35%), constipation (20-27%), diarrhea (21-25%), vomiting (13-24%), dyspepsia (12-16%), abdominal pain (13-14%), headache (8-9%), and abdominal distension (7-9%).3 Trial discontinuation due to side effects ran 5.3% to 10.3% across the orforglipron doses, compared with 2.7% on placebo.2 This side-effect pattern is the same general profile seen across the GLP-1 class - the oral, non-peptide format did not eliminate the gastrointestinal tradeoff.

How does it fit alongside injectable options?

Foundayo has not been tested head-to-head against semaglutide or tirzepatide in a published trial, so its weight-loss numbers cannot be directly ranked against the injectable comparisons already covered on this site. What it adds is a genuinely different administration format: no needle, no cold-chain pen, and none of the fasting rules that come with Rybelsus, the other oral GLP-1 already on the market.

In one sentence: Foundayo (orforglipron) is the first oral, non-peptide GLP-1 pill FDA-approved for weight loss, producing 7.4% to 11.1% average weight loss over 72 weeks depending on dose, with the same gastrointestinal tradeoffs as the rest of the drug class.